Herein, we report, for the first time, the screening of several ligands in terms of their ability to bind and stabilize G-quadruplexes (G4) found in seven human Papillomavirus (HPV) genomes. Using a variety of biophysical assays, HPV G-quadruplexes were shown to possess a high degree of structural polymorphism upon ligand binding, which may have an impact on transcription, replication, and viral protein production. A sequence found in high-risk HPV16 genotype folds into multiple non-canonical DNA structures; it was converted into a major G4 conformation upon interaction with a well-characterized highly selective G4 ligand, PhenDC3, which may have an impact on the viral infection. Likewise, HPV57 and 58, which fold into multiple G4 structures, were found to form single stable complexes in the presence of two other G4 ligands, C8 and pyridostatin, respectively. In addition, one of the selected compounds, the acridine derivative C8, demonstrated a significant antiviral effect in HPV18-infected organotypic raft cultures. Altogether, these results indicate that targeting HPV G4s may be an alternative route for the development of novel antiviral therapies.

ARNA Laboratory Université de Bordeaux Inserm U1212 CNRS UMR 5320 IECB Pessac France

Centro de Ciências e Tecnologias Nucleares Instituto Superior Técnico Universidade de Lisboa Bobadela LRS Portugal

CICS UBI Centro de Investigação em Ciências da Saúde Universidade da Beira Interior Covilhã Portugal

Department Microbiology and Immunology Penn State College of Medicine Hershey Pennsylvania USA

Institute of Biophysics of the CAS v v i Brno Czech Republic

Laboratoire d'Optique et Biosciences Ecole Polytechnique CNRS INSERM Institut Polytechnique de Paris Palaiseau France

000      

00000naa a2200000 a 4500

001      

bmc22004657

003      

CZ-PrNML

005      

20220127145100.0

007      

ta

008      

220113s2021 xxu f 000 0|eng||

009      

AR

024    7_

$a 10.1089/nat.2020.0869 $2 doi

035    __

$a (PubMed)33121376

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxu

100    1_

$a Carvalho, Josué $u CICS-UBI - Centro de Investigação em Ciências da Saúde, Universidade da Beira Interior, Covilhã, Portugal

245    10

$a Human Papillomavirus G-Rich Regions as Potential Antiviral Drug Targets / $c J. Carvalho, J. Lopes-Nunes, MPC. Campello, A. Paulo, J. Milici, C. Meyers, JL. Mergny, GF. Salgado, JA. Queiroz, C. Cruz

520    9_

$a Herein, we report, for the first time, the screening of several ligands in terms of their ability to bind and stabilize G-quadruplexes (G4) found in seven human Papillomavirus (HPV) genomes. Using a variety of biophysical assays, HPV G-quadruplexes were shown to possess a high degree of structural polymorphism upon ligand binding, which may have an impact on transcription, replication, and viral protein production. A sequence found in high-risk HPV16 genotype folds into multiple non-canonical DNA structures; it was converted into a major G4 conformation upon interaction with a well-characterized highly selective G4 ligand, PhenDC3, which may have an impact on the viral infection. Likewise, HPV57 and 58, which fold into multiple G4 structures, were found to form single stable complexes in the presence of two other G4 ligands, C8 and pyridostatin, respectively. In addition, one of the selected compounds, the acridine derivative C8, demonstrated a significant antiviral effect in HPV18-infected organotypic raft cultures. Altogether, these results indicate that targeting HPV G4s may be an alternative route for the development of novel antiviral therapies.

650    _2

$a aminochinoliny $x farmakologie $7 D000634

650    _2

$a komplement C8 $x genetika $x farmakologie $7 D003185

650    _2

$a DNA vazebné proteiny $x genetika $7 D004268

650    _2

$a G-kvadruplexy $x účinky léků $7 D054856

650    _2

$a genom virový $x účinky léků $x genetika $7 D016679

650    _2

$a genotyp $7 D005838

650    _2

$a lidský papilomavirus 16 $x účinky léků $x genetika $x patogenita $x ultrastruktura $7 D052162

650    _2

$a lidský papilomavirus 18 $x účinky léků $x genetika $x ultrastruktura $7 D052161

650    _2

$a lidé $7 D006801

650    _2

$a ligandy $7 D008024

650    _2

$a cílená molekulární terapie $7 D058990

650    _2

$a konformace nukleové kyseliny $x účinky léků $7 D009690

650    _2

$a kyseliny pikolinové $x farmakologie $7 D010848

650    _2

$a virové nemoci $x farmakoterapie $x genetika $x patologie $7 D014777

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Lopes-Nunes, Jéssica $u CICS-UBI - Centro de Investigação em Ciências da Saúde, Universidade da Beira Interior, Covilhã, Portugal

700    1_

$a Campello, Maria Paula Cabral $u Centro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico, Universidade de Lisboa, Bobadela LRS, Portugal

700    1_

$a Paulo, António $u Centro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico, Universidade de Lisboa, Bobadela LRS, Portugal

700    1_

$a Milici, Janice $u Department Microbiology & Immunology, Penn State College of Medicine, Hershey, Pennsylvania, USA

700    1_

$a Meyers, Craig $u Department Microbiology & Immunology, Penn State College of Medicine, Hershey, Pennsylvania, USA

700    1_

$a Mergny, Jean-Louis $u ARNA Laboratory, Université de Bordeaux, Inserm U1212, CNRS UMR 5320, IECB, Pessac, France $u Institute of Biophysics of the CAS, v.v.i., Brno, Czech Republic $u Laboratoire d'Optique et Biosciences, Ecole Polytechnique, CNRS, INSERM, Institut Polytechnique de Paris, Palaiseau, France

700    1_

$a Salgado, Gilmar F $u ARNA Laboratory, Université de Bordeaux, Inserm U1212, CNRS UMR 5320, IECB, Pessac, France

700    1_

$a Queiroz, João A $u CICS-UBI - Centro de Investigação em Ciências da Saúde, Universidade da Beira Interior, Covilhã, Portugal

700    1_

$a Cruz, Carla $u CICS-UBI - Centro de Investigação em Ciências da Saúde, Universidade da Beira Interior, Covilhã, Portugal

773    0_

$w MED00188196 $t Nucleic acid therapeutics $x 2159-3345 $g Roč. 31, č. 1 (2021), s. 68-81

856    41

$u https://pubmed.ncbi.nlm.nih.gov/33121376 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y p $z 0

990    __

$a 20220113 $b ABA008

991    __

$a 20220127145057 $b ABA008

999    __

$a ok $b bmc $g 1751963 $s 1155806

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2021 $b 31 $c 1 $d 68-81 $e 20201029 $i 2159-3345 $m Nucleic acid therapeutics $n Nucleic Acid Ther $x MED00188196

LZP    __

$a Pubmed-20220113